Economic evaluations of sunitinib versus interferon-alfa (IFN-α) in first-line metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Remak, E.
Mullins, C. D.
Akobundu, E.
Charbonneau, C.
Woodruff, K.
机构：
[1] United BioSource Corp, London, England
[2] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA
[3] Pfizer Inc, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6607
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A personalized sunitinib (S) first-line approach in elderly patients with metastatic renal cell carcinoma (mRCC).
    Rocca, Maria Cossu
    Iacovelli, Roberto
    Verri, Elena
    Crescio, Claudia
    Aurilio, Gaetano
    Detti, Serena
    Cullura, Daniela
    Nole, Franco
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [32] A population-based study evaluating metastatic renal cell cancer (mRCC) patients treated with interferon (IFN) alone, first-line IFN then second-line sunitinib, or sunitinib alone
    Kollmannsberger, C. K.
    Heng, D. Y.
    Murray, N.
    Chi, K. N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] COST-UTILITY ANALYSIS OF PAZOPANIB VERSUS SUNITINIB AS FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) IN SPAIN
    Espinosa, J.
    Gonzalez-Larriba, J. L.
    Maroto, P.
    Mendez-Vidal, M. J.
    Diaz-Cerezo, S.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A632 - A633
  • [34] Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
    Vazquez, Sergio
    Leon, Luis
    Fernandez, Ovidio
    Lazaro, Martin
    Grande, Enrique
    Aparicio, Luis
    [J]. ADVANCES IN THERAPY, 2012, 29 (03) : 202 - 217
  • [35] Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
    Sergio Vázquez
    Luis León
    Ovidio Fernández
    Martín Lázaro
    Enrique Grande
    Luis Aparicio
    [J]. Advances in Therapy, 2012, 29 : 202 - 217
  • [36] Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma
    Remak, Edit
    Charbonneau, Claudie
    Negrier, Sylvie
    Kim, Sindy T.
    Motzer, Robert J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) : 3995 - 4000
  • [37] ECONOMIC EVALUATION OF SUNITINIB AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN COLOMBIA
    Prieto, V. A.
    Reyes, J. M.
    Lopez-Cabra, C.
    Diaz, J. A.
    Urrego-Novoa, J. R.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A149 - A149
  • [38] Economic evaluation of sunitinib as first-line treatment for metastatic renal cell carcinoma in Mexico
    Emilio, Mucino-Ortega
    Joaquin Federico, Mould-Quevedo
    [J]. GACETA MEXICANA DE ONCOLOGIA, 2010, 9 (02): : 48 - 57
  • [39] First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC)
    Knox, J. J.
    Kay, A. C.
    Schiff, E.
    Hollaender, N.
    Rouyrre, N.
    Ravaud, A.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Hutson, Thomas E.
    Gallardo, Jorge
    Lesovoy, Vladmir
    Al-Shukri, Salman
    Stus, Viktor
    Bair, A. H.
    Rosbrook, Brad
    Bycott, Paul W.
    Tarazi, Jamal Christo
    Kim, Sinil
    Vogelzang, Nicholas J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345